Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Induced pluripotent stem cell–derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice
Silvia Espejel, … , Shinya Yamanaka, Holger Willenbring
Silvia Espejel, … , Shinya Yamanaka, Holger Willenbring
Published August 25, 2010
Citation Information: J Clin Invest. 2010;120(9):3120-3126. https://doi.org/10.1172/JCI43267.
View: Text | PDF
Research Article

Induced pluripotent stem cell–derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice

  • Text
  • PDF
Abstract

The ability to generate induced pluripotent stem (iPS) cells from a patient’s somatic cells has provided a foundation for organ regeneration without the need for immune suppression. However, it has not been established that the differentiated progeny of iPS cells can effectively reverse failure of a vital organ. Here, we examined whether iPS cell–derived hepatocytes have both the functional and proliferative capabilities needed for liver regeneration in mice with fumarylacetoacetate hydrolase deficiency. To avoid biases resulting from random genomic integration, we used iPS cells generated without viruses. To exclude compensation by hepatocytes not derived from iPS cells, we generated chimeric mice in which all hepatocytes were iPS cell derived. In vivo analyses showed that iPS cells were intrinsically able to differentiate into fully mature hepatocytes that provided full liver function. The iPS cell–derived hepatocytes also replicated the unique proliferative capabilities of normal hepatocytes and were able to regenerate the liver after transplantation and two-thirds partial hepatectomy. Thus, our results establish the feasibility of using iPS cells generated in a clinically acceptable fashion for rapid and stable liver regeneration.

Authors

Silvia Espejel, Garrett R. Roll, K. John McLaughlin, Andrew Y. Lee, Jenny Y. Zhang, Diana J. Laird, Keisuke Okita, Shinya Yamanaka, Holger Willenbring

×

Figure 1

iPS cell–derived hepatocytes facilitate NTBC-independent growth and survival of FAH-deficient mice.

Options: View larger image (or click on image) Download as PowerPoint
iPS cell–derived hepatocytes facilitate NTBC-independent growth and surv...
(A) Relative postnatal weight gain in chimeric mice compared with wild-type and FAH-deficient (KO) controls. Chimeric mice were separated into 2 groups, based on high versus no/low contribution of iPS cells to genomic DNA from digits (Supplemental Figure 1). NTBC withdrawal was initiated on P6. In contrast to KO controls and mice with no/low levels of digital chimerism, mice with high levels of digital chimerism did not require reinstatement of NTBC treatment after P22 for growth and survival. All control mice were on the 129S4 strain background, while both iPS cells and blastocysts were on a mixed 129S4 and C57BL/6 background. C57BL/6 neonates grow faster, which explains the slight difference in weight gain between control and chimeric mice between P6 and P19. (B) Quantitative RT-PCR shows that growth and survival in the absence of NTBC are strictly correlated with Fah expression in the liver. Liver Fah expression is detectable in all mice with a high iPS cell contribution to digits but not in mice with no/low levels of digital chimerism. Fah expression approaches wild-type levels with time off NTBC, increasing from approximately 50% (range, 33%–69%) in mice analyzed at P28 (left red bar) to approximately 80% (range, 76%–78%) in mice analyzed at P70 (right red bar). Maximum Fah expression levels in iPS cell chimeric mice are similar to levels found after approximately 100% liver repopulation in mice generated by injection of normal ES cells into FAH-deficient blastocysts (ESCs). (C–F) FAH immunostaining (red). Representative liver sections show that mice with (C) no or (D) low digital chimerism lack FAH-expressing cells. Livers of mice with high levels of digital chimerism show repopulation with FAH-positive cells, between approximately (E) 50% at P28 and (F) 100% at P70. Nuclei are stained blue. Scale bars: 100 μm. Data represent mean ± SEM. *P < 0.05; **P < 0.005; #P > 0.05.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts